Vitamin K1.

High dose alpha tocopherol and its quinone metabolite interfere with vitamin K dependent gamma carboxylation, which is why vitamin E carries a tolerable upper level tied to normal clotting function. Anyone taking a medicine that affects clotting should speak with a clinician before combining them.

Phylloquinone is fat soluble and needs bile salts and dietary lipid to form the mixed micelles that carry it across the intestinal wall. Taking it with an oil based serving raises the fraction absorbed compared with a dry dose on an empty stomach.

Part of absorbed K1 is converted in tissue to menaquinone-4, but K1 itself clears quickly through the liver and mostly serves hepatic carboxylation. Pairing it with K2 covers the longer circulating form that reaches bone and vascular tissue.

Vitamin D increases production of osteocalcin and matrix Gla protein, and both stay inactive until vitamin K carboxylates their glutamate residues. Raising vitamin D without adequate K leaves more of those proteins in the uncarboxylated form.

Phylloquinone is one of the two vitamin K vitamer families and feeds the same hepatic vitamin K cycle, where the epoxide reductase regenerates the reduced quinol after each carboxylation. Total vitamin K activity is the sum of both families.

Phylloquinone is cleared within hours and is taken up mainly by liver, while MK-7 circulates for days and reaches bone and arterial tissue. Part of dietary phylloquinone is also converted to MK-4 in tissue, so the families overlap without replacing each other.

Vitamin K1-dependent carboxylation creates the Gla residues that give osteocalcin and matrix Gla protein their calcium affinity. Calcium intake and vitamin K carboxylation are the two halves of directing mineral into bone matrix.

Magnesium is the cofactor for the hydroxylases that make active vitamin D, which in turn induces the Gla proteins phylloquinone carboxylates. The two act at separate points on the same sequence.

Phylloquinone is absorbed with bile salts and dietary fat through a micellar route, so an oil carrier raises the absorbed fraction over a fat-free dose. This is why plant-oil and MCT bases are standard in K1 softgels.

A randomised trial gave combined vitamins A, D, K1 and K2 to preterm infants and reported on growth and development measures, so the combination has been given together in a controlled setting. All four share fat-dependent absorption and are commonly delivered in one oily vehicle. The trial cannot separate what each vitamin contributed. In adults there is also a long-standing note that very high vitamin A intake can oppose vitamin K-dependent carboxylation, which keeps this a pairing to dose rather than to stack freely.

Phylloquinone is absorbed only after it is packaged into mixed micelles, which requires bile salts and pancreatic lipase. Where bile flow is low, fat-soluble vitamin uptake falls with it. Supplemental bile acids are used in formulations for exactly this dependency. The mechanism is physiology rather than a tested supplement pairing.

Pancreatic lipase releases fatty acids and monoglycerides from dietary triglyceride, and those are what build the micelle that carries phylloquinone across the brush border. Without lipolysis the vitamin stays in the oil phase. This is why vitamin K1 taken with a fat-containing meal is absorbed more completely than on an empty stomach. It is settled physiology.

Broad-spectrum enzyme blends supply lipase alongside protease and amylase, and the lipase fraction is the part that matters for phylloquinone uptake. The dependency is on fat digestion generally, not on any proprietary blend. It is the same mechanism as with isolated lipase, at a lower specificity.

Phospholipids from lecithin emulsify oil-soluble compounds and are used to build micellar and liposomal presentations of phylloquinone. A finer emulsion presents more surface for lipase and for micelle formation. Pharmacokinetic work on vitamin K preparations shows that the vehicle changes the blood concentration profile, which is a pharmacokinetic marker rather than an outcome. Read it as a delivery point.

Phospholipids from lecithin emulsify oil-soluble compounds and are used to build micellar and liposomal presentations of phylloquinone. A finer emulsion presents more surface for lipase and for micelle formation. Pharmacokinetic work on vitamin K preparations reports blood concentration parameters for a given preparation, which is a pharmacokinetic marker rather than an outcome, and does not on its own establish that the lecithin vehicle changes uptake. Read it as a delivery rationale.

Krill oil supplies phospholipid-bound long-chain fats, which serve as a lipid vehicle for phylloquinone in a combined softgel. The vitamin K is carried in the same oil phase and enters micelles alongside it. Marine oils also have their own effect on platelet function, so the two act on the clotting system from different directions and the combination is one to dose deliberately.

Flaxseed oil is a plant oil carrier used in vitamin K softgels, and any dietary triglyceride serves the same micelle-building role. Plant oils are in fact where much dietary phylloquinone naturally travels. The pairing is a vehicle choice rather than a nutrient interaction.

EPA and DHA shift eicosanoid production in a direction that reduces platelet aggregation, while vitamin K1 supports the carboxylation of clotting factors. The two act on different arms of haemostasis and can pull in opposite directions. This is worth stating plainly in a formulation rather than presented as a benefit. Anyone taking a vitamin K-sensitive medicine should have this reviewed by their prescriber.

High-dose vitamin E family compounds have long been described as interfering with vitamin K-dependent carboxylation, an effect attributed partly to tocopherol quinone metabolites. Tocotrienols sit in the same family and share the metabolic route. The interaction is dose-dependent and is not a concern at ordinary intakes. It is a reason to keep both at defined amounts rather than stacking high doses.

Activated charcoal adsorbs lipophilic molecules non-selectively in the gut lumen, and fat-soluble vitamins including phylloquinone are among them. Taken at the same time it reduces how much vitamin reaches the mucosa. Separating the two by several hours is the standard formulation answer. The mechanism is physical adsorption, not metabolism.

Viscous soluble fibre raises the viscosity of gut contents and binds bile acids, both of which slow micelle formation and can lower fat-soluble vitamin uptake taken in the same dose. The size of that effect at ordinary fibre intakes is modest and variable. Spacing a vitamin K1 dose away from a large fibre dose sidesteps the question. Regard it as a timing note.

Gut and food-fermenting bacteria synthesise menaquinones, the K2 side of the vitamin K family, which a systematic narrative review of microbially formed vitamins in fermented foods describes in detail. That is a different molecule from phylloquinone, which plants make and bacteria do not. The two arrive by different routes and are handled differently by tissue. Presenting bacterial production as a source of K1 would be wrong.

Nattokinase comes from natto, a fermented food that is also the richest common source of menaquinone-7, so a nattokinase preparation may or may not carry vitamin K depending on how it was purified. Nattokinase itself acts on fibrin, while vitamin K1 supports clotting factor carboxylation, so they push haemostasis in opposing directions. Label declarations should say which. This one is worth flagging rather than combining casually.

Green tea leaf is high in phylloquinone because K1 sits in the chloroplast thylakoid membranes of green leaves, so leaf-based extracts can carry measurable vitamin K depending on the extraction solvent. Aqueous catechin extracts carry little; whole leaf powder carries more. This is a composition note for anyone tracking vitamin K intake. It is not an interaction between the two actives.